The US Food and Drug Administration (FDA) has issued warning letters to website owners illegally marketing unapproved and misbranded botulinum toxin (BoNT) products.
Online, the agency stated that it is aware of adverse events associated with unapproved and misbranded BoNT products, including botulism symptoms.
A total of 18 websites were listed by the FDA, including global skincare company Derma Solution, retailer Glam Derma and medical supplier Korea Filler Experts, who were found to be selling unapproved injectable BoNT products for sale, breaking the US Food, Drug and Cosmetic Act that bans selling unapproved or misbranded drugs.
Marty Makary, FDA commissioner, said, “Unapproved and misbranded botulinum products carry serious health risks. Today we’re taking action to protect patients and prevent online entities from selling these dangerous products.”